Global Oxytocic Pharmaceutical Market, By Treatment (Pre-Eclampsia/Eclampsia, Postpartum Haemorrhage, Others), Product Type (Abortion Induced Incomplete, Inevitable Abortion, Postpartum Haemorrhage, Labor Induction, and Labor Arrest), Source of Origin (Synthetic Oxytocin, Natural Oxytocin (Animal Pituitary Extract), End User (Hospitals, Specialty Clinics, Diagnostic Centers and Others) – Industry Trends and Forecast to 2030.
Oxytocic Pharmaceutical Market Analysis and Size
Improvements in innovative oxytocic pharmaceuticals through several licensing agreements will boost sales of the market during the forecast period. Besides this, increasing usage of Antepartum oxytocin injection for improvement in uterine contractions will certainly influence the demand outlook for oxytocic pharmaceuticals. Several manufactures are focusing on adopting different strategies such as new product innovations, agreements and expansions to improve their product portfolio.
Data Bridge Market Research analyses a growth rate in the oxytocic pharmaceutical market in the forecast period 2023-2030. The expected CAGR of oxytocic pharmaceutical market is tend to be around 8.2% in the mentioned forecast period. The market was valued at USD 106.69 million in 2022, and it would grow upto USD 200.42 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Oxytocic Pharmaceutical Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Treatment (Pre-Eclampsia/Eclampsia, Postpartum Haemorrhage, Others), Product Type (Abortion Induced Incomplete, Inevitable Abortion, Postpartum Haemorrhage, Labor Induction, and Labor Arrest), Source of Origin (Synthetic Oxytocin, Natural Oxytocin (Animal Pituitary Extract), End User (Hospitals, Specialty Clinics, Diagnostic Centers and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Fresenius Kabi AG (Germany), Biofutura (Netherlands), Abbott (U.S.), JHP Pharmaceuticals (U.S.), Baxter (U.S.), Pfizer Inc. (U.S.), Ferring B.V. (Switzerland), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd (Israel)
|
|
Market Opportunities
|
|
Market Definition
Oxytocic drugs are meant to stimulate uterine activity. It is also used to control bleeding after childbirth. It is injected into a muscle, or given as an infusion into a vein. Natural oxytocin is made by extracting from the pituitary glands of the animals. Endogenous oxytocin is produced synthetically, that acts like oxytocin hormone and is approved by the U.S. FDA.
Oxytocic Pharmaceutical Market Dynamics
Drivers
- Increasing Cases of Childbirth Through Labor Induction
There has been a rising cases of childbirth using labor induction which is projected to boost growth of the global oxytocic pharmaceuticals market during the forecast period. For instance, as per the National Perinatal Information Center’s January 2019 report, induction of labor rates increased by 40% during 1997-2017 in the U.S.
- Growing Prevalence of Postpartum Haemorrhage
Increasing incidence of postpartum hemorrhage is estimated to help in growth of the market. For instance, according to the study, ‘Incidence and risk factors for postpartum hemorrhage among transvaginal deliveries at a tertiary perinatal medical facility in Japan’, published in the journal PLoS One in January 2019, the occurrence of postpartum hemorrhage was 8.7%, and of severe postpartum hemorrhage was 2.1%.
Opportunities
- Awareness of Decreasing Mortality Ratio
Growing focus of achieving mortality ratio of less than 70 per 100 000 live births in under-resourced regions is projected to offer huge growth opportunities for players in the market. For instance, according to Maternal Mortality: 1990 to 2015 Estimates by WHO, UNICEF, UNFPA, World Bank Group and the United Nations Population Division, Sub-Saharan Africa recorded the highest ratio or maternal mortality, at 555 per 100, 000 live births, from 1990 to 2015. Furthermore, the United Nations is primarily focused on achieving the Sustainable Development Goals 2015 - 2030 global maternal mortality ratio target of less than 70 per 100 000 live births.
- Increasing Adolescent Pregnancies
Growing adolescent pregnancies is projected to lead to high demand for oxytocics for labor or abortion in the region. For instance, as per the Pan American Health Organization (PAHO), the U.N. children’s agency (UNICEF), and the U.N. Population Fund (UNFPA), there were around 66.5 births per 1,000 girls aged 15 to 19 from 2010 to 2015 in Latin America compared to 46 births per 1,000 girls in the same age group globally.
Restraints/Challenges
- Existence of Alternative Drugs
The wide availability of alternative drugs is projected to obstruct growth of the global oxytocic pharmaceuticals market. Some of the alternatives for oxytocic pharmaceuticals includes misoprostol and magnesium sulphates. WHO recommends misoprostol as a low-cost, evidence-based alternative to oxytocin.
- Emerging Quality Issues of Drugs
Several quality issues associated with oxytocin preparations are also projected to hamper growth of the market. Numerous manufacturers are not obtaining WHO prequalification for manufacturing of oxytocin products, which leads to the production of substandard quality of drugs in the market.
This oxytocic pharmaceutical market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the oxytocic pharmaceutical market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development:
- In July 2019, Dr. Reddy’s Laboratories launched Carboprost Tromethamine Injection USP, a generic version of Hemabate (Pfizer). The dose approved is 250mcg/mL (1mL).
Global Oxytocic Pharmaceutical Market Scope
The oxytocic pharmaceutical market is segmented on the basis of product type, treatment, source of origin, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product Type
- Abortion Induced Incomplete
- Inevitable Abortion
- Postpartum Haemorrhage
- Labor Induction
- Labor Arrest
Treatment
- Pre-Eclampsia/Eclampsia
- Postpartum Haemorrhage
- Others
Source of Origin
- Synthetic Oxytocin
- Natural Oxytocin (Animal Pituitary Extract
End User
- Hospitals
- Specialty Clinics
- Diagnostic Centers
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacies
- Others
Oxytocic Pharmaceutical Market Regional Analysis/Insights
The oxytocic pharmaceutical market is analyzed and market size insights and trends are provided by product type, treatment, source of origin, distribution channel and end-user as referenced above.
The major countries covered in the oxytocic pharmaceutical market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
America dominates the market due to the growing recognition among patients and healthcare providers about the seriousness of the disease.
Asia-Pacific is considered the most lucrative period due to the incidence of post-partum haemorrhage, healthcare infrastructure and awareness associated with pregnancy related aspects.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Oxytocic Pharmaceutical Market Share Analysis
The oxytocic pharmaceutical market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to oxytocic pharmaceutical market.
Key players operating in the oxytocic pharmaceutical market include:
- Fresenius Kabi AG (Germany)
- Biofutura (Netherlands)
- Abbott (U.S.)
- JHP Pharmaceuticals (U.S.)
- Baxter (U.S.)
- Pfizer Inc. (U.S.)
- Ferring B.V. (Switzerland)
- Novartis AG (Switzerland)
- Teva Pharmaceutical Industries Ltd (Israel)
SKU-